Compare VVOS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | BRTX |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.4M |
| IPO Year | 2020 | 2015 |
| Metric | VVOS | BRTX |
|---|---|---|
| Price | $0.18 | $2.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 14.3M | 274.7K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,443,000.00 | $81,000.00 |
| Revenue This Year | $69.66 | $298.39 |
| Revenue Next Year | $48.38 | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $0.16 | $0.14 |
| 52 Week High | $3.70 | $4.10 |
| Indicator | VVOS | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.62 | 63.82 |
| Support Level | $0.16 | $0.51 |
| Resistance Level | $0.55 | $4.10 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 8.21 | 65.62 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.